![Breakthroughs that change patients’ lives]({"type":"image" , "src" : "/sda/112393/JournalAd-TACD-Pfizer-Leaderboard.jpg"})
References
- Heart Protection Study Colloboratve Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.
- ALLHAT Officers and Coordinators for the ALLHAT Colloborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to provastatin vs usual care: the Antihypertensive and Lipid-LoweringTreatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998–3007.
- Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcome Trial. Lancet 2003; 361: 1149–58.
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–421.
- Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P. Deedwania P. Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM; TNT Study Group; IDEAL Study Group. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008; 117:3002–9.
- Walldius G, Jungne I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur Heart J 2005; 26:210–2.
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil 5, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–72.
- The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20(supp1.1): 1183-97.
- Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002; 106:2526–9.
- FruchartJC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P. Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P; Residual Risk Reduction Initiative (R3I).The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008; 5: 319–35.
- Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361:777–80.
- Lamarche B, Moorjani 5, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, Després JP. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation 1996; 94: 273–8.
- Yusuf 5, Hawken 5, Ounpuu 5, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P. Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937–52.
- Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005; 294: 326–33.
- Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026–33.
- Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem 2009; 55:473–80.
- Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol 2008; 52:626–32.
- Wilson PW. Challenges to improve coronary heart disease risk assessment. JAMA 2009; 302: 2369–70.
- Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard By, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: Consensus Conference Report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008; 51: 1512–24.
![Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.]({"type":"image" , "src" : "/sda/112387/JournalAd-TACD-BOEHR-MPU.jpg"})
![Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.]({"type":"image" , "src" : "/sda/112392/Skyscraper_BristolMyersSquibb.jpg"})